# Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

> **NCT04299880** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Oncology

## Interventions

- **DRUG:** Napabucasin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Nivolumab
- **DRUG:** Paclitaxel
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5Fluorouracil
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04299880
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-24
- **Primary completion:** 2021-05-15
- **Final completion:** 2021-05-30
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04299880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04299880, "Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04299880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*